טוען...
Targeting the Incretin/Glucagon System With Triagonists to Treat Diabetes
Glucagonlike peptide 1 (GLP-1) receptor agonists have been efficacious for the treatment of type 2 diabetes due to their ability to reduce weight and attenuate hyperglycemia. However, the activity of glucagonlike peptide 1 receptor–directed strategies is submaximal, and the only potent, sustainable...
שמור ב:
| הוצא לאור ב: | Endocr Rev |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Endocrine Society
2018
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7263842/ https://ncbi.nlm.nih.gov/pubmed/29905825 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/er.2018-00117 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|